Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Rapamycin (Sirolimus) for Feline Hypertrophic Cardiomyopathy: RAPACAT Trial, Evidence, and Safety
The RAPACAT RCT showed low-dose delayed-release rapamycin significantly reduced LV wall-thickness progression in subclinical feline HCM at Day 180 (P=0.01), with mechanistic and ex vivo platelet-safety data now folded into one evergreen clinical reference.
Read →Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety
Atopica for Cats produced a 65.1% lesion score reduction vs 9.2% in controls in a 181-cat field study. FDA-indicated for miliary dermatitis, eosinophilic plaques, excoriations, and self-induced alopecia.
Read →Trilostane (Vetoryl) for Canine Hyperadrenocorticism: Evidence and Monitoring
Trilostane (Vetoryl) inhibits 3β-HSD for canine hyperadrenocorticism, resolving PU/PD in 70% and skin changes in 62% of dogs. Emerging evidence favours pre-trilostane cortisol over the ACTH stimulation test for monitoring clinical control.
Read →Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use
Evidence-based guide to cyclosporine (Atopica/Cyclavance) for canine atopic dermatitis: RCT efficacy vs placebo and methylprednisolone, the ~4-week onset and prednisolone bridging strategy, long-term safety, vaccination planning, CYP3A4 interactions, and feline PK contrast.
Read →Imepitoin (Pexion) for Canine Idiopathic Epilepsy: Evidence Review
Evidence-based review of imepitoin (Pexion) for canine idiopathic epilepsy — pivotal RCT efficacy, its favourable adverse-event profile versus phenobarbital, PK, and the emerging off-label feline data.
Read →Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence
Evidence-based review of maropitant (Cerenia) for vomiting in dogs and cats — canine motion sickness, feline CKD, dexmedetomidine-induced emesis comparators, and the emerging visceral-analgesia role — with NK1 mechanism and FDA label facts.
Read →Telmisartan (Semintra) for Proteinuria and Hypertension in Cats with CKD
Evergreen clinical reference on telmisartan (Semintra) for feline CKD proteinuria and systemic hypertension: the pivotal 224-cat RCT vs benazepril, FDA/EMA indications, ARB pharmacology and PK, contested aldosterone-suppression-test data, 2026 circulating-RAAS findings, and IRIS 2023 staging, phosphate, and monitoring guidance for licensed DVMs.
Read →Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
Oclacitinib (Apoquel) for canine atopic dermatitis: 24-hour onset RCT data, head-to-head vs prednisolone, ciclosporin, and ilunocitinib, 10-year safety and neoplasia evidence, JAK1 mechanism, combination protocols, and monitoring.
Read →Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
Grapiprant (Galliprant) for canine osteoarthritis: EP4 receptor antagonism mechanism, the pivotal JVIM field study (48.1% vs 31.3% success), FDA/EMA approval, meloxicam and firocoxib comparators, RCVS-appraised evidence strength, and multimodal use in young dogs and cats.
Read →Capromorelin (Entyce & Elura) for Appetite Stimulation: Evidence and Clinical Use in Dogs and Cats
The clinician's evidence hub for capromorelin — the first ghrelin (GHS-R1a) receptor agonist appetite stimulant. Covers Entyce dosing and canine field-study efficacy, the Elura feline CKD pivotal RCT (+6.81% body-weight treatment effect), comparators, adverse effects, and cardiac/glycemic precautions.
Read →Mirtazapine Transdermal Ointment (Mirataz) for Feline Weight Loss
FDA-approved mirtazapine transdermal ointment (Mirataz) for feline weight loss: pivotal field-study results, receptor mechanism, and lymphoma, CKD, and owner-adherence evidence. Includes dosing, the MAOI contraindication, and comparator guidance.
Read →Gabapentin for Pre-Visit Feline Anxiety: Evidence and Clinical Use
The evergreen clinical reference on gabapentin in cats: randomized and systematic-review evidence for pre-visit anxiolysis, the ~40% ataxia rate and 8-hour resolution window, cardiovascular safety, the pregabalin comparison, and the emerging atopic-dermatitis adjunct signal.
Read →